Abstract
Occult breast cancer presenting with axillary lymph node metastases is uncommon, and inflammatory breast cancer (IBC), as a subtype, is quite rare. Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine. Specifically, a 55-year-old woman presented with right axillary lymphadenopathy. Although she underwent various examinations, the primary site of the disease was not revealed. Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma. The patient chose to be treated by alternative medicine. About 6 months later, she was referred to our hospital, due to marked bilateral neck and axillary lymph node swelling. She presented withdiffuse right breast enlargement, redness, and peau d’orange. Computed tomography (CT) of the breast showed skin thickening and swelling of the right breast.F-18 Fluorodeoxyglucose positron emission tomography (FDG-PET) showed FDG uptake in the right breast. The patient was clinically diagnosed with IBC. Because overexpression of the human epidermal growth factor receptor 2 (HER2) was found in the specimen from her right axillary lymph node, she was treated with trastuzumab and vinorelbine. Two months after the start of chemotherapy, CT revealed a complete response in the lymph nodes, and the skin thickening and parenchymal edema of the right breast had improved. FDG-PET was also performed at this time, and revealed no FDG uptake in either the right breast or the lymph nodes.
Similar content being viewed by others
References
N Pavlidis E Briasoulis J Hainsworth et al. (2003) ArticleTitleDiagnostic and therapeutic management of cancer of an unknown primary Eur J Cancer 39 1990–2005 Occurrence Handle10.1016/S0959-8049(03)00547-1 Occurrence Handle12957453
GH Sakorafas AG Tsiotou (1999) ArticleTitleOccult breast cancer: achallenge from a surgical perspective Surg Oncol 8 27–33 Occurrence Handle10.1016/S0960-7404(99)00016-X Occurrence Handle10885391
N Ellerbroek F Holmes W Singletary et al. (1990) ArticleTitleTreatment of patients with isolated nodal metastases from an occult primary carcinoma consistent with breast origin Cancer 66 1461–1467 Occurrence Handle2207996
M Cristofanilli AU Buzdar GN Hortobágyi (2003) ArticleTitleUpdate on the management of inflammatory breast cancer The Oncologist 8 141–148 Occurrence Handle10.1634/theoncologist.8-2-141 Occurrence Handle12697939
IE Smith (2002) ArticleTitleNew drugs for breast cancer Lancet 360 790–792 Occurrence Handle10.1016/S0140-6736(02)09903-8 Occurrence Handle12241842
DJ Slamon B Leyland-Jones S Shak et al. (2001) ArticleTitleUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783–792 Occurrence Handle10.1056/NEJM200103153441101 Occurrence Handle11248153
H Kobayashi K Tanisaka N Kondo et al. (1995) ArticleTitleDevelopment of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness Jpn J Cancer Chemother 22 1933–1939
H Fukuda N Saijo (2001) ArticleTitleCommon toxicity criteria, version 2.0 Jpn J Cancer Chemother 28 1993–2027
CD Haagensen (1971) Diseases of the breast EditionNumber2nd edn. Saunders Philadelphia 576–584
NJ McCarthy X Yang IR Linnoila et al. (2002) ArticleTitleMicrovesseldensity, expression of estrogen receptor α, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer Clin Cancer Res 8 3857–3862 Occurrence Handle12473600
SA Aziz S Pervez S Khan et al. (2001) ArticleTitleCase control study of prognostic markers and disease outcome in inflammatory breast carcinoma: a unique clinical experience Breast J 7 398–404 Occurrence Handle10.1046/j.1524-4741.2001.07604.x Occurrence Handle11843851
CL Vogel MA Cobleigh D Tripathy et al. (2002) ArticleTitleEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719–726 Occurrence Handle10.1200/JCO.20.3.719 Occurrence Handle11821453
HJ Burstein LN Harris PK Marcom et al. (2003) ArticleTitleTrastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889–2895 Occurrence Handle10.1200/JCO.2003.02.018 Occurrence Handle12885806
M Pegram S Hsu G Lewis et al. (1999) ArticleTitleInhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241–2251 Occurrence Handle10.1038/sj.onc.1202526 Occurrence Handle10327070
HJ Burstein LN Harris R Gelman et al. (2003) ArticleTitlePreoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 46–53 Occurrence Handle10.1200/JCO.2003.03.124
PL Baron MP Moore DW Kinne et al. (1990) ArticleTitleOccult breast cancer presenting with axillary metastases: updated management Arch Surg 125 210–214 Occurrence Handle2302061
DJ Slamon W Godophin LA Jones et al. (1989) ArticleTitleStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707–712 Occurrence Handle2470152
DB Weiner J Nordberg R Robinson et al. (1990) ArticleTitleExpression of the neu gene-encoded protein (P185neu) in human non-small cell carcinoma of the lung Cancer Res 50 421–425 Occurrence Handle1967224
J D’Emilia K Bulovas K D’Ercole et al. (1989) ArticleTitleExpression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon Oncogene 4 1233–1239 Occurrence Handle2571966
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Asakura, H., Takashima, H., Mitani, M. et al. Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol 10, 285–288 (2005). https://doi.org/10.1007/s10147-005-0485-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10147-005-0485-x